KILITCH

KILITCH DRUGS(I)

Small Cap BSE: 524500 NSE: KILITCH
₹168.55
4.15 (2.52%)
As on 30 September, 2022 | 02:20

Kilitch Drugs(I) Share Price

Kilitch Drugs(I) Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in KILITCH DRUGS(I)

Start SIP

Kilitch Drugs(I) Share Returns

  • Over 1 Month 5.38%
  • Over 3 Month 5.57%
  • Over 6 Month 0.12%
  • Over 1 Year -0.39%

Kilitch Drugs(I) Key Statistics

P/E Ratio 31.8
PEG Ratio 0.9
Market Cap Cr 263
Price to Book Ratio 1.9
EPS 6.5
Dividend 0
Relative Strength Index 49.64
Money Flow Index 59.49
MACD Signal 0.94
Average True Range 8.29

Kilitch Drugs(I) Investment Rating

  • Master Rating:
  • Kilitch Drugs India has an operating revenue of Rs. 128.06 Cr. on a trailing 12-month basis. An annual revenue growth of 65% is outstanding, Pre-tax margin of 8% is okay, ROE of 5% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 75 which is a FAIR score but needs to improve its earnings, a RS Rating of 32 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 125 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Kilitch Drugs(I) Financials
IndicatorJun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 243231232021
Operating Expenses Qtr Cr 202828211721
Operating Profit Qtr Cr 343220
Depreciation Qtr Cr 000000
Interest Qtr Cr 000000
Tax Qtr Cr 111010
Net Profit Qtr Cr 333231

Kilitch Drugs(I) Technicals

EMA & SMA

Current Price
167.6
3.2 (1.95%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 168.21
  • 50 Day
  • 167.25
  • 100 Day
  • 170.37
  • 200 Day
  • 182.67
  • 20 Day
  • 168.96
  • 50 Day
  • 166.8
  • 100 Day
  • 163.82
  • 200 Day
  • 182.81

Kilitch Drugs(I) Resistance and Support

PIVOT
₹165.55
Resistance
First Resistance 170.1
Second Resistance 175.8
Third Resistance 180.35
RSI 49.64
MFI 59.49
MACD Single Line 0.94
MACD 0.3
Support
First Resistance 159.85
Second Resistance 155.31
Third Resistance 149.6

Kilitch Drugs(I) Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 6,185 311,910 50.43
Week 9,997 646,906 64.71
1 Month 15,718 979,053 62.29
6 Month 11,884 710,927 59.82

Kilitch Drugs(I) Result Highlights

Kilitch Drugs(I) Synopsis

NSE-Medical-Diversified

Kilitch Drugs(I) is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 70.02 Cr. and Equity Capital is Rs. 15.49 Cr. for the Year ended 31/03/2021. Kilitch Drugs(I) Ltd. is a Public Limited Listed company incorporated on 12/05/1992 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1992PLC066718 and registration number is 066718.
Market Cap 261
Sales 109
Shares in Float 0.50
No of funds 1
Yield 0.51
Book Value 1.47
U/D Vol ratio 0.8
LTDebt / Equity
Alpha 0.06
Beta 0.83

Kilitch Drugs(I)

Owner NameJun-22Mar-22Dec-21Sep-21
Promoters 68.25%68.25%68.25%
Foreign Portfolio Investors 0.03%
Financial Institutions/ Banks
Individual Investors 27.73%27.59%27.28%
Others 4.02%4.16%4.44%

Kilitch Drugs(I) Management

Name Designation
Mr. Mukund P Mehta Managing Director
Mr. Bhavin Mukund Mehta Whole Time Director
Mrs. Mira B Mehta Whole Time Director
Mr. Hemang Engineer Independent Director
Mr. Venkita Subramanian Rajan Independent Director
Prof. Vasudev Krishna Murti Independent Director

Kilitch Drugs(I) Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Kilitch Drugs(I) Corporate Action

Date Purpose Remarks
2022-08-10 Quarterly Results
2022-05-26 Audited Results
2022-02-14 Quarterly Results
2021-11-12 Quarterly Results
2021-08-13 Quarterly Results

Kilitch Drugs(I) FAQs

What is Share Price of Kilitch Drugs(I) ?

Kilitch Drugs(I) share price is ₹168 As on 30 September, 2022 | 02:06

What is the Market Cap of Kilitch Drugs(I) ?

The Market Cap of Kilitch Drugs(I) is ₹262.6 Cr As on 30 September, 2022 | 02:06

What is the P/E ratio of Kilitch Drugs(I) ?

The P/E ratio of Kilitch Drugs(I) is 31.8 As on 30 September, 2022 | 02:06

What is the PB ratio of Kilitch Drugs(I) ?

The PB ratio of Kilitch Drugs(I) is 1.9 As on 30 September, 2022 | 02:06

Q1FY23